Belite Bio sets two Euretina presentations in Vienna

• The company will present at the Euretina Innovation Spotlight on September 30, 2026.
• A separate Euretina presentation is scheduled for October 4, 2026.
• Belite Bio said the DRAGON study topline results for tinlarebant will be presented in Vienna.

Belite Bio said its data will be presented at the Euretina Innovation Spotlight on September 30, 2026, and at Euretina on October 1-4, 2026, in Vienna, Austria.

Belite Bio sets two Euretina presentations in Vienna

Innovation Spotlight

The company said Hendrik Scholl, its chief medical officer, will present a Belite Bio company overview at the EURETINA Innovation Spotlight – Inherited and Rare Retinal Diseases. The session is scheduled for September 30, 2026, from 2:28 to 3:06 p.m. CEST at the Vienna Congress & Convention Center, Room 1/Hall A.

Euretina session

Belite Bio said Michel Michaelides of Moorfields Eye Hospital and UCL Institute of Ophthalmology in London will present topline results from the Phase 3 DRAGON study of tinlarebant for adolescent Stargardt disease. That presentation is scheduled for October 4, 2026, from 1:20 to 1:27 p.m. CEST at the Vienna Congress & Convention Center, Free Paper Forum 2.

Tinlarebant

The company said tinlarebant, also known as LBS-008, is an oral therapy intended to reduce the accumulation of vitamin A-based toxins, or bisretinoids, in Stargardt disease type 1 and to contribute to disease progression in geographic atrophy, also called advanced dry age-related macular degeneration. Belite Bio said the drug has received Breakthrough Therapy Designation, Fast Track Designation and Rare Pediatric Disease Designation in the U.S., along with Orphan Drug Designation in the U.S., Europe, Japan and Switzerland, and Sakigake Designation in Japan for STGD1.

Belite Bio said its Phase 3 DRAGON trial in adolescent and adult subjects with STGD1 met its primary endpoint. It also said the FDA accepted its new drug application for tinlarebant in August 2026 with priority review, and set a Prescription Drug User Fee Act date of February 12, 2027. The company said tinlarebant is also being studied in the Phase 2/3 DRAGON II trial in STGD1 and the Phase 3 PHOENIX trial in GA.